Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | ITGAV | P06756 | 1/20 | 0.40 |
| ▸ | ITGB8 | P26012 | 1/20 | 0.40 |
| ▸ | MC1R | Q01726 | 8/20 | 0.39 |
| ▸ | MC4R | P32245 | 6/20 | 0.39 |
| ▸ | MC5R | P33032 | 6/20 | 0.39 |
| ▸ | MC3R | P41968 | 6/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | HRH2 | P25021 | 1/20 | 0.39 |
| ▸ | HRH1 | P35367 | 1/20 | 0.39 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | PLAU | P00749 | 1/20 | 0.38 |
| ▸ | SLC40A1 | Q9NP59 | 3/20 | 0.38 |
| ▸ | FLT1 | P17948 | 1/20 | 0.38 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4316809 | 0.66 | SMN1; SMN2 (1.00) | SMN1; SMN2HRH4HRH3 | |
| SCHEMBL4316806 | 0.66 | SMN1; SMN2 (1.00) | SMN1; SMN2HRH4HRH3 | |
| SCHEMBL12228287 | 0.66 | SMN1; SMN2 (1.00) | SMN1; SMN2HRH4HRH3 | |
| SCHEMBL22096056 | 0.66 | SMN1; SMN2 (1.00) | SMN1; SMN2HRH4HRH3 | |
| Livoletide SCHEMBL29373826 | 0.65 | PCSK9 (0.58) | SMN1; SMN2KLKB1 | |
| SCHEMBL4309179 | 0.64 | F2 (0.60) | MEN1 | |
| SCHEMBL30254635 | 0.63 | PLAU (0.50) | SMN1; SMN2ITGAVMEN1PLAUSLC40A1 | |
| SCHEMBL30940074 | 0.62 | HDAC4 (0.54) | — | |
| SCHEMBL14952768 | 0.61 | HDAC4 (0.56) | SMN1; SMN2 | |
| SCHEMBL14952812 | 0.58 | HDAC4 (0.55) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140141031-A1 | PATHOGENIC BACTERIA | ROYAL HOLLOWAY AND BEDFORD NEW COLLEGE (GB) | 2014-05-22 | — | — | US | claimed |
| EP-2710028-A1 | PATHOGENIC BACTERIA | Royal Holloway And Bedford New College (GB) | 2014-03-26 | — | — | EP | claimed |
| WO-2012160345-A1 | PATHOGENIC BACTERIA | ROYAL HOLLOWAY AND BEDFORD NEW COLLEGE (GB) | 2012-11-29 | — | — | WO | claimed |
| WO-2004092404-A2 | INHIBITORS OF ACIDIC MAMMALIAN CHITINASE AS ASTHMA THERAPEUTICS | WYETH (US) | 2004-10-28 | — | — | WO | claimed |
| CN-116425696-B | Oxadiazole nitrobenzguanylurea compound and preparation method and application thereof | 中国农业大学 | 2025-03-07 | — | — | CN | disclosed |
| US-20250051830-A1 | MEMBRANE-EMBEDDED NANOPORE AND USES THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY | 2025-02-13 | — | — | US | disclosed |
| CN-117924146-A | Indole methyl guanidyl urea compound and preparation method and application thereof | 中国农业大学 | 2024-04-26 | — | — | CN | disclosed |
| CN-115636773-B | Aryl ester compound containing guanylurea or guanylester, and preparation and application thereof | 中国农业大学 | 2023-11-17 | — | — | CN | disclosed |
| EP-3681504-B1 | METHODS OF DETECTION USING X-RAY FLUORESCENCE | ICAGEN INC (US) | 2023-08-23 | — | — | EP | disclosed |
| CN-116444421-A | Arylpiperidine compound containing guanidyl urea and preparation and application thereof | 中国农业大学 | 2023-07-18 | — | — | CN | disclosed |
| CN-116425696-A | Oxadiazole nitrobenzguanylurea compound and preparation method and application thereof | 中国农业大学 | 2023-07-14 | — | — | CN | disclosed |
| WO-2023064805-A1 | MEMBRANE-EMBEDDED NANOPORE AND USES THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2023-04-20 | — | — | WO | disclosed |
| EP-1951868-A2 | INTEGRATION OF SAMPLE STORAGE AND SAMPLE MANAGEMENT FOR LIFE SCIENCE | Biomatrica, Inc. (US) | 2008-08-06 | — | — | EP | disclosed |
| US-20080176209-A1 | INTEGRATION OF SAMPLE STORAGE AND SAMPLE MANAGEMENT FOR LIFE SCIENCE | BIOMATRICA, INC. (US) | 2008-07-24 | — | — | US | disclosed |
| EP-1893614-A1 | INHIBITOR COMPOUNDS | The University Court of the University of Dundee (GB) | 2008-03-05 | — | — | EP | disclosed |
| WO-2007098033-A2 | FEEDBACK PRODRUG | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC . (US) | 2007-08-30 | — | — | WO | disclosed |
| WO-2007075253-A2 | INTEGRATION OF SAMPLE STORAGE AND SAMPLE MANAGEMENT FOR LIFE SCIENCE | BIOMATRICA, INC. (US) | 2007-07-05 | — | — | WO | disclosed |
| WO-2006136822-A1 | INHIBITOR COMPOUNDS | UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) | 2006-12-28 | — | — | WO | disclosed |
| US-20060099567-A1 | Desolventizing, dehydration, dryness; for automated storing, tracking retrieving and analyzing of nucleic acid samples; refrigeration-free | BIOMATRICA, INC. (US) | 2006-05-11 | — | — | US | disclosed |
| WO-2004092404-A2 | INHIBITORS OF ACIDIC MAMMALIAN CHITINASE AS ASTHMA THERAPEUTICS | WYETH (US) | 2004-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060099567-A1 | Desolventizing, dehydration, dryness; for automated storing, tracking retrieving and analyzing of nucleic acid samples; refrigeration-free | DNASE1, DCTD, DNASE1L3 | SMN1; SMN2 2055/4885ITGAV 2166/4885ITGB8 2507/4885 |
| US-20080176209-A1 | INTEGRATION OF SAMPLE STORAGE AND SAMPLE MANAGEMENT FOR LIFE SCIENCE | NEFM, DNASE1, DCTD | SMN1; SMN2 359/4885ITGAV 1731/4885ITGB8 1853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.